Active, Avidex cancer deal

Active Biotech (SSE:ACTI) and Avidex (Oxford, U.K.) partnered to develop targeted immunotherapeutics for cancer. Under the deal, ACTI will combine its superantigen protein platform with Avidex's tumor...